 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12...5859606162636465666768...8687» |
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, prednisolone / Generic mfg.
[VIRTUAL] TREATMENT STATUS FOR OSTEOPOROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: CROSS-SECTIONAL ANALYSIS FROM A LUPUS REGISTRY OF NATIONWIDE INSTITUTIONS (LUNA) () - May 22, 2020 - Abstract #EULAR2020EULAR_3496;
About a quarter of patients with SLE did not take any treatment for osteoporosis. Treatment for osteoporosis might be strengthened to prevent bone damage in SLE patients with CKD.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] TREATMENT WITH DENOSUMAB IN GLUCOCORTICOSTEROID-INDUCED OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS () - May 22, 2020 - Abstract #EULAR2020EULAR_3468;
Denosumab should be considered as a drug of choice in RA patients, continuing to receive GCS. Further large investigations are needed to assess the BMD after discontinuation of denosumab and evaluate fracture risk in this population of patient.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, zoledronic acid / Generic mfg.
[VIRTUAL] BONE MINERAL DENSITY AND FRACTURE RISK IN A COHORT OF PORTUGUESE SYSTEMIC SCLEROSIS PATIENTS (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_3209;
FRAX appears to be an useful instrument as it correlated with spine fractures, contrary to what was verified when we used the WHO threshold. Early monitoring of BMD and estimating fracture risk using FRAX appear to be useful tools for the prevention of fractures in this population.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] DELAYED DENOSUMAB INJECTIONS AND FRACTURES RISK AMONG SUBJECTS WITH OSTEOPOROSIS: A POPULATION-BASED COHORT STUDY (Poster Tour) - May 22, 2020 - Abstract #EULAR2020EULAR_2694;
Early monitoring of BMD and estimating fracture risk using FRAX appear to be useful tools for the prevention of fractures in this population. While delayed subsequent denosumab dosages over 16 weeks was associated with an increased risk of vertebral and major osteoporotic fracture compared to no delay, composite fracture risk was not increased with longer delays.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] INDICATORS OF EFFECTIVENESS AFTER 6 YEARS OF FOLLOW-UP OF PATIENTS IN THE FLS DR. NEGRIN (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_2494;
When analyzing patients with prescribed treatment, in 176 cases (72%) it was a bisphosphonate in a sustained manner, in 23 cases (9%) a bisphosphonate was prescribed and subsequently changed to denosumab, while in 45 cases (18%) it was initiated and maintained denosumab... After an average of 6 years after the assessment in an FLS, the persistence of treatment was 62% (MPR≥80% in 51%), the mortality was 23% and the percentage of refractured patients was 17%.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] GOAL-DIRECTED TREATMENT OF OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS USING DENOSUMAB FOR FIVE YEARS (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_2335;
Early initiation or longer duration of DMB therapy may be necessary to improve achievement rates. Likewise, other agents, such as romosozumab, may be considered for those with significant TH-BMD loss.
- [VIRTUAL] DIFFERENT PROFILE OF RISK OF FRACTURE IN PATIENTS TREATED WITH ANTI-OSTEOPOROTIC DRUGS IN ITALY USING A NEW ALGORITHM (Poster Tour) - May 22, 2020 - Abstract #EULAR2020EULAR_2257;
Teriparatide is prescribed to patients with greater risk of fracture. The Nota 79 correctly individuates patients at very high risk of fracture that merit treatment with a bone anabolic.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] PATIENTS DEMOGRAPHIC CHARACTERISTICS WITH ESTABLISHED OSTEOPOROSIS TREATED WITH DENOSUMAB IN A THIRD LEVEL HOSPITAL () - May 22, 2020 - Abstract #EULAR2020EULAR_1971;
Complete adherence to treatment has been observed in 73% of patients. We have not observed vertebral fractures after suspension of Denosumab in our series of patients, although the total exposure time (from the end of treatment to the end of follow-up) is short: 2.77 years
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, prednisone / Generic mfg., zoledronic acid / Generic mfg.
[VIRTUAL] REAL-LIFE RISK OF FRACTURE AND TREATMENT PREVALENCE IN DRUG-INDUCED OSTEOPOROSIS IN ITALY USING A NEW ALGORITHM (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_1944;
Women with glucocorticoid-induced osteoporosis had a greater risk of fracture compared to patients treated with adjuvant hormone therapy for breast cancer. Half of the patients on adjuvant hormone therapy for breast cancer were prescribed with denosumab.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] COMPLIANCE AND PERSISTENCE OF ANTI-OSTEOPOROTIC TREATMENTS IN PATIENTS WITH HIP FRACTURE (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_1830;
It is necessary to investigate which factors may lead to the detection of potential non-compliant patients. It seems appropriate to consider drugs that facilitate compliance and permanence of treatment.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] BONE LOSS AND NEW FRACTURES WITH DENOSUMAB TREATMENT () - May 22, 2020 - Abstract #EULAR2020EULAR_1777;
BMD loss seems to be more marked at spine than total hip. Only one patient had a secundary cause of IR.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] FACTORS THAT DEMONSTRATED SIGNIFICANT CORRELATION WITH BONE MINERAL DENSITY GAIN WITH DENOSUMAB ADMINISTRATION FOR PATIENT WITH RHEUMATOID ARTHRITIS () - May 22, 2020 - Abstract #EULAR2020EULAR_1580;
These results suggested that BMD gain in LS and FN was affected by different factors. These results may be helpful reference in choosing denosumab against osteoporosis in RA patient.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] WHAT DETERMINES THE EFFECT OF THERAPY WITH DENOSUMAB ON BONE IN WOMEN WITH RHEUMATOID ARTHRITIS AND OSTEOPOROSIS (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_1547;
The mean change of BMD (%) after 12 months was +4,6% at L1-L4, at HN +2,8%, at DF +0,7%. Positive response on denosumab (BMD) was noted in 89% patients at L1-L4, 67% - at HN and 60% - at DF.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] VITAMIN D LEVELS IN PRIMARY CARE AND RHEUMATOLOGY PATIENTS () - May 22, 2020 - Abstract #EULAR2020EULAR_1247;
The 55% of the patients studied in primary care and rheumatology, without renal, digestive or bone disease and without vitamin D supplement, presented vitamin levels below the actual limits of 30ng/ml. These limits, used by most of the laboratories, tend to overestimate the vitamin D deficiency.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, zoledronic acid / Generic mfg.
[VIRTUAL] TERIPARATIDE SWITCH TO BIOSIMILAR - IS IT COST EFFECTIVE? () - May 22, 2020 - Abstract #EULAR2020EULAR_1208;
Despite that teriparatide remains effective for a wide range of individuals including those with inflammatory arthritis and/or concurrent steroid use. Neither moderate CKD nor mild Vit D insufficiency seems to impact its efficacy.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
[VIRTUAL] SHORT-TERM MONITORING OF DENOSUMAB EFFECT IN BREAST CANCER PATIENTS RECEIVING AROMATASE INHIBITORS USING REMS TECHNOLOGY ON LUMBAR SPINE (Poster View) - May 22, 2020 - Abstract #EULAR2020EULAR_1168;
Several studies have shown the effect of denosumab on BMD over a period not less than 2 years from the start of treatment. This study showed the feasibility of short-term follow-up using REMS lumbar spine scans at 6-month time steps.
- ||| Prolia (denosumab) / Amgen
Trial primary completion date: Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI (clinicaltrials.gov) - May 21, 2020
P3, N=153, Active, not recruiting, Sponsor: Amgen
This study showed the feasibility of short-term follow-up using REMS lumbar spine scans at 6-month time steps. Trial primary completion date: Jan 2020 --> Jan 2022
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Reply to Letter to the Editor RE: Further Nonvertebral Fracture Reduction Beyond 3 Years for up to 10 Years of Denosumab Treatment. (Pubmed Central) - May 21, 2020
Trial primary completion date: Jan 2020 --> Jan 2022 No abstract available
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Letter to the Editor: "Further nonvertebral fracture reduction beyond 3 years for up to 10 years of denosumab treatment". (Pubmed Central) - May 21, 2020
No abstract available No abstract available
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Letter to the Editor: "Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use". (Pubmed Central) - May 21, 2020
No abstract available No abstract available
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal, Combination therapy: Combination therapies in the treatment of osteoporosis. (Pubmed Central) - May 21, 2020
The knowledge of modern data as to when the potential use of combination therapy in treating osteoporosis may be useful is critical to the acquisition of proficiency in the ideal management of our patients at highest risk for fracture. Although not recommended yet by current guidelines, the advancement of expertise in this field, both in research studies, and clinical practice, will help us discern how to best consider the use of combination treatment now and in the future.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice. (Pubmed Central) - May 19, 2020
Early investigation for mBD offers a prognostic marker of patients with NENs, since synchronous mBD has a negative impact on survival. The outcome of bone-related therapy affects OS but the monthly administration of bisphosphonates did not show a benefit over less intense schemes.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Review, Journal: The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment. (Pubmed Central) - May 19, 2020
Several antiresorptive drugs, like bisphosphonates and denosumab, are currently available for the treatment of osteoporosis due to their evidenced efficacy in reducing fracture risk at mid-term...This review reports the currently available clinical evidence on the discontinuation effects of different anti-osteoporotic drugs, as well as the clinical outcomes of the different sequential treatment regimens. The objective of this article is to present up-to-date practical knowledge on this area in order to provide guidance to the clinicians involved in the management of patients with osteoporosis.
- | Herceptin (trastuzumab) / Roche
Journal: Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas. (Pubmed Central) - May 19, 2020
The results indicate a novel physical and molecular association between ERBB-2 and RANK pathways that affects ERBB-2 (+) BC growth. We also present data suggesting that the combination of anti-ERBB-2 agents and RANKL inhibitors have a potential direct anti-tumor effect and should be further tested in certain BC patients.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Review, Journal: What is the relationship between bone turnover markers and skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma? A systematic review and meta-regression analysis. (Pubmed Central) - May 19, 2020
We included randomized controlled trials of adults (≥18 years old) with bone metastases from solid tumors (including breast, lung, prostate) or bone lesions from multiple myeloma that compared denosumab or bisphosphonate(s) with each other or a placebo...The limitation of this review is that it depends on how comprehensive study data were that could be included in the meta-regression. Our findings support a positive relationship between reduction of bone turnover markers at the earliest time of steady state and reduction in longer-term risk of SREs.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, zoledronic acid / Generic mfg.
Also need to be on Zometa or Denosumab as Radium + Abi had high # risk, not seen with Enza + Ra (Twitter) - May 18, 2020
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Observational data, Retrospective data, Journal: A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers. (Pubmed Central) - May 16, 2020
Multivariate analysis showed a statistically significant correlation between DRONJ and hormone therapy (odds ratio [OR], 22.07; 95% confidence interval [CI], 2.86-170.24), chemotherapy and/or molecular targeted therapy (OR, 18.61; 95% CI, 2.54-136.27), and apical periodontitis (OR, 22.75; 95% CI, 3.20-161.73). These findings imply that collaborative oral examinations by oral specialists may reduce the risk of development of DRONJ in patients treated with denosumab for bone metastases from solid cancers.
- Zytiga (abiraterone acetate) / J&J, Xofigo (radium Ra-223 dichloride) / Bayer
The effects of prednisone, abiraterone acetate and radium-223 dichloride on bone in the intratibial LNCaP prostate cancer model (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_538;
This preclinical mechanism may nevertheless contribute to the increased fragility observed in the clinics and may explain the beneficial clinical effects of bone resorption-inhibiting bisphosphonates and denosumab. However, several species- and model-related factors may limit the translational relevance of these findings.
- Reproducible, MoA-reflecting reporter-based bioassays to enable drug development of biosimilars and biobetters (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_3798;
We demonstrate these assays measure cytokine response and inhibition with blocking drugs or potency changes from stressed samples. In summary, these reporter-based bioassays provides valuable tools for the development, stability testing, and potency determination in the manufacture of cytokine biosimilars and biobetters.
- KLF5 acetylation promotes bone metastatic growth of prostate cancer by activating CXCR4/IL-11 and subsequent osteoclast differentiation (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_1317;
More importantly, targeting CXCR4 using FDA approved drugs AMD3100 selectively sensitizes Ac-KLF5-expressing tumors and bone metastases to docetaxel treatment. These findings provide a rationale for targeting Ac-KLF5/CXCR4 signaling as a novel therapeutic strategy in advanced prostate cancer patients with bone metastases.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone. (Pubmed Central) - May 15, 2020
For the curettage, the denosumab-induced changes had mixed impacts, and shorter term (fewer than six doses) usage may be more appropriate. Our six-dose regime was deemed safe, while the safety of long-term use remains unknown.
- Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, zoledronic acid / Generic mfg.
[VIRTUAL] Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss () - May 15, 2020 - Abstract #ENDOI2020ENDO-I_115;
Our six-dose regime was deemed safe, while the safety of long-term use remains unknown. Treatment with ZOL irrespective of the timing did not fully prevent loss of BMD in patients with osteopenia.
- Evenity (romosozumab) / Astellas, Amgen, UCB
[VIRTUAL] Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis () - May 15, 2020 - Abstract #ENDOI2020ENDO-I_114;
The treatment effect of Romo continued after patients transitioned to an antiresorptive agent. These data will help to foster treatment decisions in postmenopausal women at high risk for VFx.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Absolutely, It’s a bit like they’re not accepting to Denosumab for metastatic NSCLC (Twitter) - May 14, 2020
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Interview: An Interview with Dr. Barry Gruber on Why you Can't Delay Denosumab infusions. Watch it here>> https://t.co/XKQ9a0p1nJ or listen on iTunes https://t.co/FHJv01AAbC or SoundCloud https://t.co/zUlIDAFmtA (Twitter) - May 14, 2020
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Giant cell tumor of the eleventh thoracic vertebra in a pediatric patient: an interesting case report and comprehensive literature review. (Pubmed Central) - May 13, 2020
The main purpose of the treatment is gross total resection of the giant cell tumor. However, adjuvant methods such as denosumab should be added to the treatment protocol in patients who are older than 2 years old and can not undergo gross total resection due to tumor size and anatomic localization.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Denosumab for treating aneurysmal bone cysts in children. (Pubmed Central) - May 13, 2020
The immediate adverse effect profile is acceptable. A larger study with a longer follow-up would be welcome to further assess the contribution of denosumab to the treatment of ABC.
- | Review, Journal: Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications. (Pubmed Central) - May 9, 2020
Post-hoc analyses of randomised studies have shown that the efficacy of drugs such as alendronate, risedronate, raloxifene, teriparatide and denosumab is similar to that of the general population in patients with a mild/moderate decline in their glomerular filtration rate (especially CKD-3)...However, we must also be aware that most studies are not consistent and the level of evidence is low. Consequently, any pharmacological intervention (risk/benefit) should be prudent and individualised.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Denosumab-treated Giant Cell Tumors of Bone: A Clinicopathologic Analysis of 35 Cases From the French Group of Bone Pathology. (Pubmed Central) - May 9, 2020
The histologic response, despite the absence of objective regression of the mononuclear cells, was associated with an enhanced progression-free survival. Greater numbers of giant cells represented the only predictive indication of an optimal histologic response to denosumab treatment.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Review, Journal: Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review. (Pubmed Central) - May 8, 2020
In 2 studies, patients were being treated with denosumab, but neither showed that a drug holiday was effective...This study concluded that drug holiday was not necessary. Thus, there are no evidence for using drug holiday, but it is also clear that caused by a limited numbers of eligible patients, and a great variation in between these patient, high-level evidence for using AR drug holiday is almost impossible to obtain.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Retrospective data, Review, Journal: The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis. (Pubmed Central) - May 8, 2020
Additionally, denosumab resulted in significant increases in BMD in the lumbar spine and femoral neck at 12 months compared with bisphosphonate therapy. Patients with GIO experienced significant increases in BMD in response to treatment with denosumab that were detected in the lumbar spine, total hip and femoral neck at 12 months.
- | Review, Journal: Treating osteoporosis to prevent fractures: current concepts and future developments. (Pubmed Central) - May 7, 2020
For patients with severe osteoporosis and high fracture risk, bisphosphonates alone are unlikely to be able to provide long-term protection against fracture and restore BMD. For those patients, sequential treatment, starting with a bone-building drug (e.g. teriparatide), followed by an antiresorptive, will likely provide better long-term fracture prevention and should be the golden standard of future osteoporosis treatment.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Journal: Glucocorticoid-induced osteoporosis update. (Pubmed Central) - May 7, 2020
GIOP and fragility fractures are important adverse events related to the long-term use of glucocorticoids. Recent studies have provided additional data on the epidemiology and pathogenesis of GIOP and on the efficacy and effectiveness of GIOP therapies.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Predictors of denosumab efficacy in treating osteoporosis in patients with rheumatoid arthritis: a Japanese multicenter study. (Pubmed Central) - May 6, 2020
In conclusions, denosumab increased BMD in RA patients with osteoporosis. The combined use of biologics and denosumab may provide useful treatment options.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Evenity (romosozumab) / Astellas, Amgen, UCB, zoledronic acid / Generic mfg.
Clinical, Journal: Combination and sequential treatment in women with postmenopausal osteoporosis. (Pubmed Central) - May 6, 2020
Combination therapy with teriparatide and denosumab or zoledronate has achieved higher BMD gains compared to each agent alone; however, due to the high cost, combination therapy is rarely compensated. On the contrary, the combination of teriparatide with alendronate results in smaller BMD increases than TPTD monotherapy.
- Medical Benefit (Part B) Drug Step Therapy and the Utilization Management Implications for Medicare Advantage Plans () - May 6, 2020 - Abstract #AMCP2020AMCP_306;
Increased use of lower cost similar efficacy alternatives lead to reduced drug spend on Part B specialty medications. Sponsorship: Emergent Holdings for Blue Cross Blue Shield of Michigan
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Reimbursement, Journal: Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients? (Pubmed Central) - May 2, 2020
Sponsorship: Emergent Holdings for Blue Cross Blue Shield of Michigan Our findings suggested that osteoporosis treatment should be initiated in younger age, especially in men, in order to avoid osteoporotic fractures in Japan.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, Journal: Low rate of densitometric diagnosis and treatment in patients with severe osteoporosis in Colombia. (Pubmed Central) - May 2, 2020
Our study shows that Colombian patients have little knowledge about osteoporosis and its relationship with fragility fractures. It also shows that densitometries are not done and, what is worse, patients with a diagnosis of fracture have limited access to treatment after discharge.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
Clinical, P4 data, Journal: The utilization and challenges of Japan's MID-NET medical information database network in postmarketing drug safety assessments: A summary of pilot pharmacoepidemiological studies. (Pubmed Central) - May 1, 2020
The use of laboratory test results to define clinical outcomes may allow more objective and accurate analyses to be conducted. These studies furthered our understanding of the characteristics of MID-NET , including its advantages and limitations.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Evenity (romosozumab) / Astellas, Amgen, UCB
Journal: Cellular Communication in Bone Homeostasis and the Related Anti-osteoporotic Drug Development. (Pubmed Central) - May 1, 2020
Current anti-osteoporosis therapies are effective but accompanied by certain drawbacks simultaneously. Restoring the abnormal signal network and individualized therapy are critical for the ideal drug development.